Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name TGFbetaR2KO/IL13Ralpha2 CAR-T cells
Synonyms
Therapy Description

TGFbetaR2KO/IL13Ralpha2 CAR-T cells are autologous T-lymphocytes engineered with knockout of TGFbRII expression and to express a chimeric antigen receptor (CAR) targeting IL13Ra2, which potentially induce toxicity in IL13Ra2-expressing tumor cells (NCI Thesaurus).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
TGFbetaR2KO/IL13Ralpha2 CAR-T cells Autologous TGF-betaR2KO/IL13R-alpha2-CAR T Cells|TGFbRII-KO/IL-13Ra2 CAR T-cells IL13RA2 Immune Cell Therapy 7 TGFbetaR2KO/IL13Ralpha2 CAR-T cells are autologous T-lymphocytes engineered with knockout of TGFbRII expression and to express a chimeric antigen receptor (CAR) targeting IL13Ra2, which potentially induce toxicity in IL13Ra2-expressing tumor cells (NCI Thesaurus).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06815029 Phase I TGFbetaR2KO/IL13Ralpha2 CAR-T cells Intracranial Genetically Modified Immune Cells (TGFbetaR2KO/IL13Ralpha2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma Recruiting USA 0


Additional content available in Icon for CKB-BoostCKB BOOST